Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Carparts.Com Inc (PRTS) Price & Performance

Gilead Sciences, Inc.Trade
Carparts.Com IncTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Carparts.Com Inc — how do they compare? Gilead Sciences, Inc. trades at $135.49 (market cap $164.99B), while Carparts.Com Inc trades at $6.41 (market cap $52.07M). The key difference: Gilead Sciences, Inc. is far larger — about 3168.6× Carparts.Com Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.

GILDPRTS
Market Cap
$164.99B$52.07M
Sector
HealthConsumer Cyclical
52-Week High
$155.80$11.40
52-Week Low
$110.56$3.88
Enterprise Value
$188.06B$67.05M
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Carparts.Com Inc

CarParts.com (PRTS) is trading at $6.75, up 16.68% with bullish technical signals and strong analyst support. The company shows improving operational performance with three consecutive quarterly earnings beats, though it remains unprofitable with negative net margins. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25 million credit facility, providing financial flexibility amid challenging market conditions.

The outlook remains cautiously optimistic with 60% analyst buy ratings supporting recovery potential, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investors should focus on the company's ability to leverage proprietary data advantages while monitoring progress toward profitability in the competitive auto parts e-commerce sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS